Preiato, V.L., Salvagni, S., Ricci, C., Ardizzoni, A., Pagotto, U. and Pelusi, C. (2021) Diabetes Mellitus Induced by Immune Checkpoint Inhibitors: Type 1 Diabetes Variant or New Clinical Entity? Review of the Literature. Reviews in Endocrine and Metabolic Disorders, 22, 337-349.
https://doi.org/10.1007/s11154-020-09618-w

has been cited by the following article:

• TITLE: Long-Term Persistent Absolute Insulin Secretion Deficiency in Diabetes Induced by Immune Checkpoint Inhibitors

  AUTHORS: Moctar Bah, Clara Bouché, Jean-François Gautier

  KEYWORDS: Immune Checkpoint Inhibitors, Nivolumab, Ipilimumab, Fulminant Diabetes, Insulin-Requiring Diabetes

  JOURNAL NAME: Open Journal of Endocrine and Metabolic Diseases, Vol.13 No.12, December 27, 2023

  ABSTRACT: Immune checkpoint inhibitors are today an immense hope in the management of cancers. However, since their widespread use, many cases of insulin-requiring diabetes appearing suddenly, as fulminant diabetes have been reported. Here, we describe 4 cases that occurred at different times after the beginning of immune checkpoint inhibitor therapy with Nivolumab alone or associated with Ipilimumab. There are 3 cases of newly diagnosed diabetes and 1 case of known type 2 diabetes formerly quite well balanced with Metformin. The clinical and biological characteristics of these patients are quite similar. They were all insulin-requiring at the discovery of diabetes and remained so throughout their follow-up. This type of diabetes which looks like type 1 diabetes seems rather to be a new entity.